| Parameter | n | Treatment response | Progression-free survival | Overall survival | |||
| ORR (%) | P value (Fisher test) | Median (months) | P value (log-rank test) | Median (months) | P value (log-rank test) | ||
| Gender |
|
|
|
|
|
|
|
| Male | 22 | 73 | 0.38 | 8.6 | 0.26 | 36.0 | 0.33 |
| Female | 8 | 50 |
| 7.0 |
| 25.3 |
|
| Age (years) |
|
|
|
|
|
|
|
| <75 | 23 | 74 | 0.18 | 8.6 | 0.85 | 27.8 | 0.47 |
| ≥75 | 7 | 43 |
| 7.3 |
| 32.7 |
|
| Primary tumor site |
|
|
|
|
|
|
|
| Right-sided | 7 | 43 | 0.18 | 3.5 | 0.00031 | 16.7 | 0.025 |
| Left-sided | 23 | 74 |
| 10.6 |
| 36.0 |
|
| Other RAS genotype |
|
|
|
|
|
|
|
| Wild-type | 23 | 70 | 0.66 | 10.0 | 0.089 | 36.0 | 0.26 |
| Mutant-type | 7 | 57 |
| 7.9 |
| 23.2 |
|
| ECOG PS at baseline |
|
|
|
|
|
|
|
| 0 - 1 | 26 | 73 | 0.095 | 8.6 | 0.0030 | 32.7 | 0.000013 |
| 2 - 3 | 4 | 25 |
| 1.3 |
| 4.4 |
|
| Lymph node metastasis at baseline |
|
|
|
|
|
|
|
| Positive | 15 | 73 | 0.70 | 8.1 | 0.40 | 32.7 | 0.70 |
| Negative | 15 | 60 |
| 8.9 |
| 25.3 |
|
| Peritoneal metastasis at baseline |
|
|
|
|
|
|
|
| Positive | 6 | 67 | 1 | 8.6 | 1.0 | 27.8 | 0.21 |
| Negative | 24 | 67 |
| 8.1 |
| 32.7 |
|
| Histological grade at baseline |
|
|
|
|
|
|
|
| 1 - 2 | 25 | 76 | 0.031 | 8.6 | 0.13 | 36.0 | 0.022 |
| 3 - 4 | 5 | 20 |
| 1.5 |
| 23.2 |
|
| CEA at baseline |
|
|
|
|
|
|
|
| <5.0 ng/ml | 13 | 38 | 0.0069 | 4.1 | 0.40 | 23.2 | 0.0043 |
| ≥5.0 ng/ml | 17 | 88 |
| 10.0 |
| 44.8 |
|
| Oxaliplatin-including treatment regimen |
|
|
|
|
|
|
|
| Yes | 24 | 71 | 0.37 | 8.1 | 0.74 | 36.0 | 0.069 |
| No | 6 | 50 |
| 8.9 |
| 23.2 |
|
| Oxaliplatin-based adjuvant chemotherapy |
|
|
|
|
|
|
|
| Yes | 7 | 57 | 0.66 | 8.1 | 0.44 | 32.7 | 0.79 |
| No | 23 | 70 |
| 8.9 |
| 27.8 |
|